🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

218 results for “Merck” Clear

  1. Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Gastrointestinal Cancers

    phase 3 small molecule active

    1 trial

  2. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  3. SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept

    Merck Sharp and Dohme

    ​​Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  4. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil

    Merck Sharp and Dohme

    HIV-1 prevention

    phase 3 small molecule active

    1 trial

  6. Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine

    United Therapeutics Europe Ltd

    COVID-19

    phase 3 small molecule terminated

    1 trial

  7. Vericiguat, Vericiguat, Vericiguat, Vericiguat

    Merck Sharp and Dohme

    Heart Failure due to Systemic Left Ventricular Systolic Dysfunction

    phase 3 small molecule active

    1 trial

  8. XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  10. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  12. tulisokibart, tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  13. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial

  14. -, -, -, MK-1200, -, -

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  15. -, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  16. -, PREDNISONE, PARACETAMOL , FLUDROCORTISONE , ABIRATERONE , -, HYDROCORTISONE, -, Ifinatamab Deruxtecan, -, -, HYDROCORTISONE, HYDROCORTISONE, Opevesostat, DOCETAXEL , ENZALUTAMIDE , PREDNISOLONE

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  17. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  18. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

  19. A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  20. A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 other active

    1 trial

  21. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  22. Belzutifan, PALBOCICLIB

    Merck Sharp and Dohme

    Advanced ccRCC

    phase 2 small molecule active

    1 trial

  23. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  24. CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources